EKF Diagnostics: Flat Revenue, Fat Margins, and a Quiet Land-Grab in U.S. Blood Banks
H1 2026 top line stalls at £25m, but a Life Sciences rebrand, a £5.9m buyback, and the Blood Centers of America deal tell a growth story hiding in plain sight
EKF.L · Earnings Call · 2026-09-15
A Flat Top Line, Better Bones
EKF Diagnostics is a £114m-market-cap, AIM-listed diagnostics group tucked into the Healthcare / Medical Devices corner of the market, and on 15 September it delivered interim H1 2026 results that superficially look like nothing happened: group revenue was "broadly flat at GBP 25 million," a shade under a percent lower year on year. But the mix underneath moved. Gross margin strengthened roughly three points to 53%, adjusted EBITDA ticked up 2.4% to £5.9m (a 23.6% margin), and basic EPS rose a striking 26% to 0.54p. “Financially, we delivered a strong first half, and importantly, in line with expectations... the quality of that resilience improved, with gross margin up” — Helen Jones, CFO · 2026-09-15, new CFO Helen Jones told investors — she has been in seat only since April 2026, part of a refreshed leadership team alongside CEO Gavin Jones (in the top job since March 2025). The company framed the half as the fourth consecutive year of first-half EBITDA growth, a deliberate reframing away from the headline revenue number.Point-of-Care vs Life Sciences: A Deliberate Divergence
The halves of the company pulled in opposite directions. Point of Care — the rapid-test devices sold into 120+ countries — printed £15m, down 3%, while Life Sciences rose a pleasing 8% to £10m. Management's spin is that the Point-of-Care dip is timing, not demand: key tenders closed later than expected, pushing deliveries into H2, and lactate production ran behind schedule. Crucially, that inventory is sitting on the balance sheet, not lost. “I think it is important to state that this is deferred revenue, not lost revenue, and we expect to see it come through fully in the second half.” — Gavin Jones, CEO · 2026-09-15 The detail rewards a closer read. Hematology was flat at £7.8m, but Hemo Control remains the largest contributor and the DiaSpect is a close second, with the HemataStat II up 9% as availability returned. Diabetes was flat overall, yet management cites the Quo-Lab gaining share from the Quo-Test as reimbursement dynamics reset — a portfolio flexing rather than losing ground. Life Sciences is the real engine: BHB product (the ketone-testing franchise) at £7.4m, contract manufacturing up 25% to £1m, and fermentation up 40% to £1.6m. That Life Sciences strength is not a company-only signal either — the phrase ranked inside the global market's editor-curated top-75 for 20262 (rank 13), so EKF is riding a broader Life Sciences wave rather than inventing one.Blood Banks, Bioworks, and the Strategic Pivots
The genuinely new material this quarter is strategic. In March EKF signed with the Blood Centers of America, opening a U.S. blood bank opportunity that management sizes in the Q&A: a ~$60m market, of which roughly 40% is locked up by the American Red Cross, leaving the independent banks under the BCA umbrella as the addressable prize. Three U.S. blood banks are now live with DiaSpect and three more come online in H2 — a rare, concrete commercial proof point. Second, the Life Sciences division gets a new identity: its contract manufacturing and fermentation offering is being rebranded as Nexus Bioworks, a rebrand management argues will speed client conversion by making a four-decade-old business legible to pharma and biotech buyers. Third, the small April acquisition of Beep Insights adds a mobile app layer — with AI elements — to the sports-performance / lactate franchise, extending consumables pull.All of this builds towards our 2029 target, which is to deliver revenues above GBP 80 million and adjusted EBITDA above GBP 20 million, roughly double where we are today.